The 340B Drug Discount Program is a US federal government program that enables covered entities to stretch scarce resources. Created in 1992, it requires drug manufacturers to provide outpatient drugs to eligible healthcare organizations and covered entities at significantly reduced prices, enabling them to reach more patients and provide comprehensive services within underserved populations.


Hover over the images below to see how the 340B Program and HIV rapid testing help your community.

See below to learn how the 340B Program and HIV rapid testing help your community.
hiv_new4321


1. More than 1.1 million people in the United States are living with HIV
  • 1 in 7 are unaware of their infection and are unable to benefit from the advances made in HIV treatment

  • Late presentation for HIV care is associated with higher mortality 2
2. Rapid testing encourages more people to get tested3
  • Ensures more people receive their results4

  • OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test delivers results in 20 minutes

  • Enables patients to learn their status and get connected to care in a single visit

  • Portable devices provide the ability to test individuals who would not come to a facility for testing
3. Early and consistent access to HIV treatment can reduce the likelihood of a person transmitting the disease by 96%5
  • Advances in treatment mean that HIV-positive individuals can have a similar life expectancy as people uninfected
4. The 340B Program can help launch and maintain sustainable testing and treatment programs
  • Cost savings for FDA-approved HIV treatments can be as much as $6000/patient per year

  • Cost savings gained can be used for anything directly involving patient care, including co-pays, charity care pharmacies, additional rapid tests, outreach programs, and staff support

  • Additional resources enables healthcare organizations to reach more patients, continuing the cycle and providing healthcare support to all those who need it

By using the 340B cost savings to implement rapid testing programs you are widening the possible reach of your facility and cutting down the window of time between detection and linkage to care. The OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test requires 3 easy steps and delivers results within 20 minutes, allowing for immediate linkage to care. Rapid testing also provides peace of mind to the patient as they receive their results same day while face-to-face with their health care provider and have the opportunity to create a treatment plan before they leave. Not only does this simplify the process of linking someone to care, it cuts out the time spent trying to contact the patient to get them to come back in to receive their results.

For more information visit www.OraSure.com/Request.




Does your organization also do HCV testing? Click Here.


1. CDC. HIV in the United States: At a Glance, June 2017
2. Late Presentation for Human Immunodeficiency Virus Care in the United States and Canada, Althoff, 2010.
3. Mascolini, Mark. Three Biggest HIV Problems in the United States: Late Testing, Late Care, Early Dropout, Research Initiative Treatment Action, Vol. 16, No. 1.
4. Calderon, etal. HIV Test Preferences in an Urban Hospital Emergency Department, HIV Diagnostics Conference, 2010.
5. Cohen MS, etal. HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS 2012; 7: 99– 105.